3036 G-CSF use and neutropenic events in patients with breast and lung tumours: data from routine clinical practice (IMPACT Solid study)
Krzysztof Krzemieniecki(Jagiellonian University), S K Verma, Henrik Lindman(Uppsala University), Matthias Schwenkglenks(University of Basel), Martin Šmakal(Nemocnice Na Pleši), Ioannis Varthalitis(Chania General Hospital ”St. George”), Johanna Mäenpää(Tampere University Hospital), J. Puertas, P. Sevelda, Frans Erdkamp
Cited by 1
Related Papers
Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer
|Annals of Oncology|2014|603
Breast Cancer in Young Women: Poor Survival Despite Intensive Treatment
|PLoS ONE|2009|504
Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial
|The Lancet|2000|343
Measuring HER2-Receptor Expression In Metastatic Breast Cancer Using [<sup>68</sup>Ga]ABY-025 Affibody PET/CT
|Theranostics|2015|269
First-in-Human Molecular Imaging of HER2 Expression in Breast Cancer Metastases Using the <sup>111</sup>In-ABY-025 Affibody Molecule
|Journal of Nuclear Medicine|2014|260